AI and RNA genetic medicine company Genetic Leap partners with pharmaceutical giant Eli Lilly develops gene therapy drugs.
According to the companies, the collaboration expands a pilot program leveraging Genetic Leap’s RNA-targeting AI platform designed to produce oligonucleotide medicines against targets selected by Lilly in important therapeutic areas.
Lilly will pay Genetic Leap up to $409 million in upfront commercial, development, regulatory and clinical payments as well as tiered royalties.
According to the company, RNA plays a critical role in regulating key biological processes and holds great potential in addressing serious diseases that are not effectively targeted by existing medicines.
“We are excited to collaborate with Lilly and share their strong commitment to developing RNA medicines,” Dr. Bertrand Advances, CEO and founder of Genetic Leap, said in a statement.
“Our primary goal in building the Genetic Leap AI platform is to accelerate the development of medicines that save patients’ lives, and this collaboration with Lilly’s talented and knowledgeable research and development team brings us significantly closer to that goal.”
Larger trends
In 2022, A genetic leap Partnered with Astellas Pharma to develop novel RNA-targeted small molecule therapeutic candidates against undisclosed tumor targets. Genetic Leap has deployed its platform to discover and validate RNA-targeted small molecules against undisclosed tumor targets selected by Astellas Pharma.
Another company involved in AI/RNA genetic medicine is Deep Genomics, a Canadian startup whose artificial intelligence technology is designed to help program and prioritize innovative RNA therapeutics for genetic diseases, has raised $180 million in Series C funding.
The company also developed the APAI Workbench, a proprietary platform to decipher the complexities of RNA biology and find new targets, mechanisms and molecules inaccessible via traditional methods.
The HIMSS Healthcare Cybersecurity Forum is scheduled to take place October 31-November 1 in Washington, DC. More information and registration.
